Squarepoint
SNDX icon

Squarepoint’s Syndax Pharmaceuticals SNDX Stock Holding History

Squarepoint’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.24M Buy
181,552
+161,738
+816% +$3.51M 0.01% 1624
2025
Q4 		$416K Sell
19,814
-15,705
-44% -$274K ﹤0.01% 3351
2025
Q3 		$546K Sell
35,519
-1,738
-5% -$22.7K ﹤0.01% 3165
2025
Q2 		$349K Buy
+37,257
New +$410K ﹤0.01% 3570
2024
Q1 		– Sell
-52,035
Closed -$1.12M – 4572
2023
Q4 		$1.12M Buy
52,035
+22,915
+79% +$352K ﹤0.01% 2444
2023
Q3 		$423K Sell
29,120
-10,163
-26% -$192K ﹤0.01% 2920
2023
Q2 		$822K Buy
+39,283
New +$818K ﹤0.01% 2314
2021
Q3 		– Sell
-32,575
Closed -$559K – 3390
2021
Q2 		$559K Buy
32,575
+5,936
+22% +$109K ﹤0.01% 2046
2021
Q1 		$596K Sell
26,639
-64,488
-71% -$1.46M ﹤0.01% 1889
2020
Q4 		$2.03M Buy
91,127
+25,643
+39% +$532K 0.02% 936
2020
Q3 		$967K Buy
65,484
+45,171
+222% +$689K 0.01% 1016
2020
Q2 		$301K Sell
20,313
-12,043
-37% -$183K ﹤0.01% 1601
2020
Q1 		$355K Buy
+32,356
New +$304K 0.01% 1212
2019
Q1 		– Sell
-18,601
Closed -$83K – 2415
2018
Q4 		$83K Buy
18,601
+6,303
+51% +$34.6K ﹤0.01% 1814
2018
Q3 		$99K Buy
+12,298
New +$87.7K ﹤0.01% 1886
2018
Q1 		– Sell
-10,216
Closed -$89K – 2110
2017
Q4 		$89K Buy
+10,216
New +$101K ﹤0.01% 1972

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Squarepoint's SNDX Position: Q1 2026 in Review

Squarepoint increased its Syndax Pharmaceuticals (SNDX) stake by 816% in Q1 2026, buying an estimated $3.51M and bringing the position to 181,552 shares worth $4.24M. The position accounts for 0.01% of the portfolio, ranked #1624.

Squarepoint first reported a position in SNDX in Q4 2017 and has held it in 16 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Squarepoint held 181,552 shares of Syndax Pharmaceuticals worth $4.24M as of Q1 2026.
  • Squarepoint bought 161,738 Syndax Pharmaceuticals shares in Q1 2026, an estimated $3.51M.
  • Syndax Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q1 2026, its #1624 holding.
  • Squarepoint first reported a position in Syndax Pharmaceuticals in Q4 2017 and has held it in 16 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.